Showing 1,381 - 1,400 results of 12,750 for search '"therapeutics"', query time: 0.10s Refine Results
  1. 1381
  2. 1382
  3. 1383

    Timing of Therapeutic Extractions Can Affect En Masse Anterior Retraction: A Split Mouth Randomized Clinical Trial by Devi Priya, Shobha Sundareswaran, Navnita Mishra, SreehariSathyanathan, Mohammed Shibin, Baby Jisha

    Published 2024-12-01
    “…Objective: To investigate the effect of deferred timing of therapeutic extraction on the rate of space closure during en masse anterior retraction. …”
    Get full text
    Article
  4. 1384

    Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate by Tobias M. Prass, Patrick Garidel, Lars V. Schäfer, Michaela Blech

    Published 2024-12-01
    “…Model systems composed of two marketed therapeutic IgG1 monoclonal antibodies with identical Fc domain sequences, trastuzumab and omalizumab, were investigated with commonly used excipients arginine, glutamate, and equimolar arginine/glutamate mixtures. …”
    Get full text
    Article
  5. 1385

    Immunometabolic alterations in type 2 diabetes mellitus revealed by single-cell RNA sequencing: insights into subtypes and therapeutic targets by Huahua Li, Lingling Zou, Zhaowei Long, Junkun Zhan, Junkun Zhan

    Published 2025-01-01
    “…The identification of critical TFs and the development of drug enrichment profiles highlight the potential for personalized therapeutic strategies, emphasizing the need for integrated immunological and metabolic approaches in T2DM management.…”
    Get full text
    Article
  6. 1386
  7. 1387

    Recent Pathophysiological Aspects of Peyronie’s Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment—Literature Review by Gianni Paulis, Gennaro Romano, Luca Paulis, Davide Barletta

    Published 2017-01-01
    “…While conservative therapies commonly used in the early stages of PD include oral substances (Potaba, tamoxifen, colchicine, and vitamin E), intralesional treatment (verapamil, interferon, steroids, and more recently collagenase clostridium histolyticum-Xiaflex), and local physical treatment (iontophoresis, extracorporeal shock wave therapy, and penile extender), the significant results obtained by emerging treatments with the antioxidants cited in this article suggest these therapeutic agents interfere at several levels with the disease’s pathogenetic mechanisms. …”
    Get full text
    Article
  8. 1388

    Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia by Juan Li, Chunmei Ye, Hui Li, Jun Li

    Published 2025-12-01
    “…In vivo studies with cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models demonstrated that CX-4945 and venetoclax combined therapy provided superior therapeutic efficacy, reducing tumor burden and prolonging survival compared to single-agent treatments.Conclusions IKZF1 represses BCL-2 in T-ALL, and targeting the CK2-IKZF1 axis with CX-4945 and venetoclax offers a promising therapeutic strategy, showing enhanced efficacy and potential as a novel treatment approach for T-ALL.…”
    Get full text
    Article
  9. 1389
  10. 1390

    Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study by Zhihao Fang, Guohong Ren, Shouyu Ke, Qimin Xu, Yuhua Chen, Xiaoyuan Shi, Cheng Guo, Jian Huang

    Published 2025-01-01
    “…Finally, we discovered that the therapeutic effects of NACT could be attributed to essential amino acid metabolism. …”
    Get full text
    Article
  11. 1391
  12. 1392
  13. 1393

    Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles in ischemic stroke: A meta-analysis of preclinical studies by Xiaoming Zhang, Yibing Guo, Kun Fang, Xiangqian Huang, Duo Lan, Mengqi Wang, Lina Jia, Xunming Ji, Ran Meng, Da Zhou

    Published 2025-02-01
    “…Background: Ischemic stroke (IS) remains a significant global health burden, necessitating the development of novel therapeutic strategies. This study aims to systematically evaluate the therapeutic effects of mesenchymal stem cell-derived exosomes (MSC-Exos) on IS outcomes in rodent models. …”
    Get full text
    Article
  14. 1394

    Identification of SETD4 as an Onco‐Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers by Yuyun Zhong, Ruiqi Wang, Zijie Huang, Zhaoting Hu, Bin Peng, Bin Chen, Liyue Sun

    Published 2025-01-01
    “…A limited number of systematic studies have examined SETD4's role in the tumor microenvironment, pathogenesis, prognosis, and therapeutic response. Methods Utilizing The Cancer Genome Atlas database, and other publicly accessible platforms, we comprehensively analyzed SETD4 gene expression, methylation patterns, and prognostic significance. …”
    Get full text
    Article
  15. 1395
  16. 1396

    Computational network analysis of two popular skin cancers provides insights into the molecular mechanisms and reveals common therapeutic targets by Md Sujan Mahmud, Bikash Kumar Paul, Md. Rakibul Hasan, K.M. Tanjida Islam, Imran Mahmud, Shahin Mahmud

    Published 2025-01-01
    “…Therefore, this study aims to elucidate the common molecular pathways and potential therapeutic targets for BCC and AK through comprehensive computational network analysis. …”
    Get full text
    Article
  17. 1397

    Anti-Diabetic Therapeutic Medicinal Plant Identification Using Deep Fused Discriminant Subspace Ensemble (D2SE) by N. Sasikaladevi, S. Pradeepa, A. Revathi, S. Vimal, Gaurav Dhiman

    Published 2025-01-01
    “…Finally, the model is integrated into a mobile app for robust classification of anti-diabetic therapeutic medicinal plant with real field images.…”
    Get full text
    Article
  18. 1398
  19. 1399

    NT5E (CD73) as a prognostic biomarker and therapeutic target associated with immune infiltration in lung adenocarcinoma by Leyan Chen, Tuoya Qi, Bishu Zhang, Xuelong Wang, Mingfeng Zheng

    Published 2025-02-01
    “…Collectively, these findings establish NT5E as a promising prognostic biomarker and therapeutic target in LUAD, particularly in the context of immune cell infiltration.…”
    Get full text
    Article
  20. 1400